Group 1 - The total net subscription amount for equity ETFs from January 9 to January 13 reached 47.303 billion yuan [1] - Popular thematic ETFs saw significant interest, with the GF Media ETF net subscription amounting to 7.064 billion yuan, the Yongying Satellite ETF at 4.901 billion yuan, and the Southern CSI 1000 ETF at 4.193 billion yuan [1] - Other ETFs such as the Southern Nonferrous Metals ETF, Harvest Software ETF, and Fortune Satellite ETF also had net subscriptions exceeding 2 billion yuan [1] Group 2 - Hong Kong stock thematic ETFs also attracted attention, with the Fortune Hong Kong Internet ETF net subscription at 2.475 billion yuan and the GF Hong Kong Non-bank ETF at 1.539 billion yuan [1] - The Huatai-PB Southern Dongying Hang Seng Technology ETF and the E Fund Hong Kong Stock Connect Innovative Drug ETF both had net subscriptions exceeding 1.1 billion yuan [1]

Group 1 - The article presents a neutral stance on the opinions expressed by the author, indicating that the views do not represent the website's position [1] - The content emphasizes the importance of readers conducting their own research and taking responsibility for their decisions [1] Group 2 - The article does not provide specific data or insights related to companies or industries [1] - There are no financial metrics or performance indicators mentioned in the content [1]

Group 1 - The index focuses on leading innovative drug companies in the A-share market, consisting of no more than 50 stocks primarily involved in innovative drug research and development [4] - As of the midday close, the index has decreased by 1.5%, with a rolling price-to-earnings ratio of 53.3 times and a valuation increase of 80.9% since its launch [5] - The biotechnology ETF tracks the China Securities Biotechnology Theme Index, which also focuses on leading biotechnology companies in the A-share market, comprising stocks related to gene diagnosis, biopharmaceuticals, blood products, and other human biotechnology [6][7] Group 2 - The pharmaceutical ETF tracks the CSI 300 Healthcare Index, focusing on leading companies in the A-share pharmaceutical and healthcare sector, covering segments such as chemical pharmaceuticals, medical services, and medical devices [9] - As of the midday close, this index has decreased by 0.4%, with a rolling price-to-earnings ratio of 31.1 times and a valuation increase of 48.5% since its launch [10]